Collectively, these findings establish the anti-mitogenic effect of ASK1 inhibition and identify ASK1 as a novel pathway that can be targeted to reduce or prevent excessive ASM mass in COPD. Here, MAP3K5 is linked to chronic obstructive pulmonary disease.